Centre for Applied Medical Research, St. Vincent's Hospital, Australia; Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Inserm, U955, Equipe 16, Créteil, 94000, France; Université Paris Est, Faculté de médecine, Créteil, 94000, France; Vaccine Research Institute (VRI), Créteil, 94000, France; AP-HP, Hôpital H. Mondor-A. Chenevier, Service d'immunologie Clinique et maladies infectieuses, Créteil, 94000, France.
Cytokine Growth Factor Rev. 2014 Aug;25(4):391-401. doi: 10.1016/j.cytogfr.2014.07.012. Epub 2014 Jul 29.
Interleukin-7 is a non-redundant growth, differentiation and survival factor for human T lymphocytes. Most circulating, mature T cells express the receptor for IL-7, but not all. Importantly, CD4 Tregs express greatly reduced levels of IL-7R compared to conventional CD4 T cells, presenting an opportunity to selectively target the latter cells with either more IL-7 to boost responses, or to block IL-7 signalling to limit responses. This article reviews what is known about regulation of IL-7R expression, and recent progress in therapeutic approaches related to IL-7 and its receptor.
白细胞介素-7 是一种非冗余的生长、分化和生存因子，可促进人类 T 淋巴细胞的生长。大多数循环的成熟 T 细胞表达白细胞介素-7 的受体，但并非全部。重要的是，与传统的 CD4 T 细胞相比，CD4 Tregs 表达的 IL-7R 水平大大降低，这为我们提供了一个机会，可以选择性地用更多的 IL-7 来增强后者的反应，或者阻断 IL-7 信号来限制反应。本文综述了 IL-7R 表达的调控及其受体的治疗方法的最新进展。
